A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

S*BIO

Status and phase

Completed

Phase 2

Conditions

Hodgkin Lymphoma

Indolent Lymphoma

Mantle Cell Lymphoma

Treatments

Drug: SB1518

Study type

Interventional

Funder types

Industry

Identifiers

NCT01263899

SB1518-2010-005

Details and patient eligibility

About

This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).

Enrollment

28 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with histologically documented diagnosis of one of the following lymphoid malignancies:
Hodgkin Lymphoma;
Mantle Cell Lymphoma;
Indolent Lymphoma (including follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma);
Patients must have received at least one prior treatment regimen; patients with Hodgkin Lymphoma must have received an autologous stem cell transplant, refused or been deemed ineligible for stem cell transplant;
Able to understand and willing to sign the informed consent form.

Exclusion criteria

Any histology other than Hodgkin Lymphoma, Mantle Cell Lymphoma or Indolent Lymphoma;
History of or active Central Nervous System (CNS) malignancy;
Active graft-versus-host disease (GVHD);